LAVAL, Québec--(BUSINESS WIRE)--Altasciences is proud to support Alzamend Neuro, Inc. (Alzamend) in advancing a novel treatment for dementia related to Alzheimer’s disease (Alzheimer’s). In addition ...

Altasciences, a nine-time CRO Leadership Award winner, is proud to announce they have been awarded a 2025 CDMO Leadership Award in the Small Molecule Dosage Form–North America category. This press ...

LAVAL, Quebec--(BUSINESS WIRE)--Altasciences, a trusted drug development research partner for over 30 years, continues its commitment to providing world-class bioanalytical services. This core ...

LAVAL, Québec, August 21, 2025--(BUSINESS WIRE)--Altasciences is pleased to have been chosen by Steel Therapeutics, Inc. ("Steel"), to initiate a pivotal toxicology study for Fizurex™, a novel topical ...

Laval, Quebec-based Altasciences has acquired WCCT Global, a Cypress, California-based early-stage clinical research organization. No financial terms were disclosed. Altasciences, a CRO specializing ...

LAVAL, Québec, August 27, 2025--(BUSINESS WIRE)--Altasciences, a fully integrated CRO/CDMO offering comprehensive early-phase drug development solutions, is pleased to announce a strategic ...

LAVAL, Quebec — Altasciences today announced the completion of the acquisition of a preclinical testing business in Everett, Washington. This transaction will support Altasciences’ goal of being a mid ...

Altasciences, a forward-thinking CRO/CDMO supporting all crucial steps in early-stage drug development, from lead candidate selection to clinical proof of concept, announced today that they have ...

LAVAL, Québec--(BUSINESS WIRE)--#Biotech--Altasciences hired two expert advisors to support its strategic growth in Europe, while its preclinical team continues to expand with the addition of two key ...

LAVAL, Quebec--(BUSINESS WIRE)--#CDMO--Altasciences, a fully integrated early phase CRO/CDMO has started the expansion of their CDMO facility in Philadelphia, PA. The additional 35,000-square-foot ...

Altasciences Clinical Research and QPS Holdings, two private-equity-backed pharmaceutical-services companies focused on early-phase drug development, are exploring potential sales, according to ...

Altasciences is pleased to have been chosen by Steel Therapeutics, Inc. (“Steel”), to initiate a pivotal toxicology study for Fizurex™, a novel topical therapy for the treatment of anal fissures. The ...